Jelena Kunovac
Psychiatry · Las Vegas, NVNPI 1851402259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $864,121 of the $1,240,962 with a category attached, or 69.6%. 17 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 25.2% of the total. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,123 payments — averaging $1105.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$313K
- Alkermes, Inc.$301K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$234K
- E.r. Squibb & Sons, L.L.C.$124K
- Axsome Therapeutics, Inc.$96K
- Sunovion Pharmaceuticals Inc.$74K
- plus $99K from 11 others
Across 1,165 payments — averaging $9575.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$3M
- AbbVie$2.8M
- Sage Therapeutics, LLC$1.4M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.3M
- Bioxcel Therapeutics, Inc.$481K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$398K
- plus $1.8M from 28 others
What the payments were for
- Consulting fees$225,37218%
- Speaking & faculty fees$864,12170%
- Travel & lodging$131,39911%
- Food & beverage$20,0702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 294 | $313,104 |
| Alkermes, Inc. | 286 | $300,531 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 203 | $234,472 |
| E.r. Squibb & Sons, L.L.C. | 107 | $123,758 |
| Axsome Therapeutics, Inc. | 77 | $95,938 |
| Sunovion Pharmaceuticals Inc. | 69 | $73,830 |
| Vanda Pharmaceuticals Inc. | 47 | $60,524 |
| Johnson & Johnson | 27 | $20,515 |
| Indivior Inc. | 3 | $11,185 |
| Livanova USA, Inc. | 3 | $6,276 |
| Avanir Pharmaceuticals, Inc. | 1 | $425 |
| Lundbeck LLC | 1 | $109 |
| Tris Pharma Inc | 1 | $107 |
| Janssen Research & Development, LLC | 1 | $106 |
| Merck | 1 | $32 |
| Boston Scientific | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$705,557
- LYBALVI$481,115
- CAPLYTA$231,617
- ARISTADA INITIO$164,577
- ABILIFY MAINTENA$155,169
- REXULTI$148,014
- Auvelity$95,264
- LATUDA$72,127
- Fanapt$60,388
- COBENFY$55,509
- ABILIFY ASIMTUFII$54,221
- SPRAVATO$20,265
- PERSERIS$11,185
- VNS Therapy Symmetry Model 8103 Generator$6,276
- Dyanavel XR$107
How this compares
$1,240,962 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
- John VallesLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.